Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A.

J Clin Oncol. 2008 Nov 10;26(32):5156-64. doi: 10.1200/JCO.2008.17.2015. Epub 2008 Oct 14.

PMID:
18854568
2.

Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice.

Hagenbeek A.

Leuk Lymphoma. 2003;44 Suppl 4:S37-47. Review.

PMID:
15154741
3.
4.

Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.

Witzig TE.

Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S91-5. Review.

PMID:
11587375
5.

Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.

Morschhauser F, Dreyling M, Rohatiner A, Hagemeister F, Bischof Delaloye A.

Oncologist. 2009;14 Suppl 2:17-29. doi: 10.1634/theoncologist.2009-S2-17. Review.

6.

Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma.

Sánchez Ruiz AC, de la Cruz-Merino L, Provencio Pulla M.

Ther Adv Hematol. 2014 Jun;5(3):78-90. doi: 10.1177/2040620714532282. Review.

7.

Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.

Zinzani PL, d'Amore F, Bombardieri E, Brammer C, Codina JG, Illidge T, Jurczak W, Linkesch W, Morschhauser F, Vandenberghe E, Van Hoof A.

Eur J Cancer. 2008 Feb;44(3):366-73. doi: 10.1016/j.ejca.2007.12.008. Epub 2008 Jan 14.

PMID:
18194857
8.

Radioimmunotherapy in follicular lymphoma.

Illidge T, Morschhauser F.

Best Pract Res Clin Haematol. 2011 Jun;24(2):279-93. doi: 10.1016/j.beha.2011.03.005. Epub 2011 May 12. Review.

PMID:
21658624
9.

Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin).

Gregory SA.

Semin Oncol. 2003 Dec;30(6 Suppl 17):17-22. Review.

PMID:
14710399
10.

Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies.

Seiler T, Hiddemann W, Dreyling M.

Immunotherapy. 2009 Nov;1(6):1015-24. doi: 10.2217/imt.09.55. Review.

PMID:
20635916
11.

Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.

Wagner HN Jr, Wiseman GA, Marcus CS, Nabi HA, Nagle CE, Fink-Bennett DM, Lamonica DM, Conti PS.

J Nucl Med. 2002 Feb;43(2):267-72. Review.

12.

Radioimmunotherapy in follicular lymphoma: some like it hot….

Kersten MJ.

Transfus Apher Sci. 2011 Apr;44(2):173-8. doi: 10.1016/j.transci.2011.01.015. Epub 2011 Feb 21. Review.

PMID:
21334979
13.

[Current treatment of follicular lymphoma].

Bonnet C, Beguin Y, Deprijck B, de Leval L, Fillet G.

Rev Med Suisse. 2009 Aug 26;5(214):1663-7. Review. French.

14.

Zevalin(®) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?

Rizzieri D.

Crit Rev Oncol Hematol. 2016 Sep;105:5-17. doi: 10.1016/j.critrevonc.2016.07.008. Epub 2016 Jul 16. Review.

PMID:
27497027
15.

Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis.

Auger-Quittet S, Duny Y, Daures JP, Quittet P.

Cancer Med. 2014 Aug;3(4):927-38. doi: 10.1002/cam4.247. Epub 2014 Apr 16. Review.

16.

A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma.

Rose AC, Shenoy PJ, Garrett G, Seward M, Kucuk RA, Doksansky H, Nastoupil LJ, Flowers CR.

Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):393-9. doi: 10.1016/j.clml.2012.09.012. Review.

PMID:
23158095
17.

Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom?

Forstpointner R, Dreyling M.

Curr Hematol Malig Rep. 2011 Dec;6(4):207-15. doi: 10.1007/s11899-011-0099-5. Review.

PMID:
21909660
18.

Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.

Vidal L, Gafter-Gvili A, Leibovici L, Dreyling M, Ghielmini M, Hsu Schmitz SF, Cohen A, Shpilberg O.

J Natl Cancer Inst. 2009 Feb 18;101(4):248-55. doi: 10.1093/jnci/djn478. Epub 2009 Feb 10. Review.

PMID:
19211444
19.

[Therapy of follicular lymphoma].

Buske C, Unterhalt M, Hiddeman W.

Internist (Berl). 2007 Apr;48(4):372-81. Review. German.

PMID:
17287964
20.

[Contribution of radioimmunotherapy to the treatment of lymphoma].

Rizzo-Padoin N.

Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8. doi: 10.1016/j.pharma.2008.09.003. Epub 2008 Nov 8. Review. French.

PMID:
19061730

Supplemental Content

Support Center